Key Highlights
- Amazon One Medical introduced a comprehensive GLP-1 weight management service that integrates telehealth consultations, prescriptions, and direct pharmacy delivery.
- For insured customers, monthly costs begin at $25; self-pay options for injectable treatments like Wegovy and Zepbound start at $299 per month.
- The e-commerce giant aims to extend same-day medication delivery services to 4,500 urban areas by late 2026.
- Shares of Hims & Hers (HIMS) plummeted up to 6% during pre-market hours after the program announcement.
- Analysts at Bank of America forecast the competitive challenge could reduce HIMS’s GLP-1 business by 31%.
Amazon has officially entered the weight management pharmaceutical sector with significant force. The company revealed on Tuesday its new GLP-1 treatment program via Amazon One Medical, its healthcare division, creating an all-in-one solution that combines obesity therapy with pharmaceutical services and remote medical appointments.
The service provides patients with brand-name weight loss medications such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Customers with insurance coverage can obtain oral GLP-1 medications for as little as $25 monthly. For those paying out-of-pocket, oral formulations begin at $149 per month, whereas injectable treatments like Wegovy and Zepbound carry a starting price of $299 monthly.
While these price points align with existing market rates, Amazon‘s competitive edge lies in operational efficiency — leveraging its powerful delivery infrastructure to offer same-day service combined with a streamlined patient experience from initial assessment through ongoing prescription management.
Tanvi Patel, Vice President and General Manager of Amazon Pharmacy, emphasized that the objective is simplifying adherence by ensuring medications “are delivered reliably directly to patients.”
Currently operational throughout the United States, the program treats weight management as an ongoing medical condition requiring sustained care rather than short-term intervention. It encompasses preliminary health assessments, organized medical consultations, regular follow-up appointments, and clinically validated treatment approaches.
Patients can also request prescription renewals on demand, with messaging consultations priced at $29 and video appointments at $49. The company has announced plans to bring same-day delivery capabilities to 4,500 metropolitan areas by 2026’s conclusion.
Hims & Hers Faces Market Pressure
The program launch dealt a significant blow to Hims & Hers Health. HIMS shares declined as much as 6% during early trading hours, although the stock recovered somewhat as the day progressed. The market response underscores investor anxiety about Amazon entering the affordable GLP-1 segment that HIMS has actively cultivated.
The development comes at a particularly sensitive moment for HIMS. The telehealth company has recently pivoted toward branded weight loss pharmaceuticals — the premium market tier — precisely when Amazon introduces a competing integrated offering. Bank of America analysts have cautioned this competitive threat could slash HIMS’s GLP-1 revenue stream by 31%.
Additional companies associated with the obesity treatment market also experienced downward pressure Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
Amazon’s Growing Presence in Weight Loss Medications
Tuesday’s announcement represents Amazon’s latest expansion in the GLP-1 sector, not its inaugural venture. The company introduced same-day delivery for Novo Nordisk’s Wegovy obesity medication in January. By April, it had extended same-day fulfillment to Eli Lilly’s recently approved weight-loss pill, Foundayo, via its online pharmacy platform.
This week’s launch consolidates these separate initiatives into a cohesive ecosystem — unifying primary medical care, pharmaceutical services, and telehealth appointments within one comprehensive platform.
Regarding market sentiment, AMZN maintains a Strong Buy rating from 45 Wall Street analysts — comprising 42 Buy recommendations and 3 Hold ratings. The consensus price target of $286.74 suggests approximately 13% potential appreciation from present trading levels.
Shares of AMZN stock increased by roughly 1% in response to the announcement.
